General Principles of Pharmacology

Genetic variation in drug-metabolizing enzymes produces a spectrum of enzyme activity across the population. Four phenotypes are defined. Poor metabolizers carry genetic variants that abolish enzyme activity entirely. Intermediate metabolizers have reduced activity. Extensive metabolizers — the majority of the population — have normal activity. Ultrarapid metabolizers have increased activity, usually because they carry extra copies of the gene encoding the enzyme.

The clinical consequence of these phenotypes depends on whether the drug being metabolized is an active compound or a prodrug that requires metabolic activation. For an active drug, poor metabolizers accumulate higher drug concentrations and are at increased risk of dose-dependent toxicity at standard doses. Ultrarapid metabolizers clear the drug so rapidly that standard doses fail to reach therapeutic concentrations. For a prodrug requiring metabolic activation to its active form, the consequences reverse: poor metabolizers generate insufficient active drug and may not respond to treatment, while ultrarapid metabolizers generate toxic concentrations of the active metabolite.

Codeine is a prodrug that must be converted by the cytochrome P450 2D6 enzyme to morphine, its active analgesic metabolite. In poor metabolizers, this conversion does not occur: codeine produces no meaningful analgesia because morphine is never generated. In ultrarapid metabolizers, the conversion is so rapid and complete that a standard codeine dose generates morphine concentrations equivalent to a much larger morphine dose, causing respiratory depression and potentially fatal toxicity.

Both ends of this spectrum produce preventable patient harm. The ultrarapid metabolizer risk is particularly serious in nursing mothers: a case of fatal neonatal morphine toxicity from a mother who was a cytochrome P450 2D6 ultrarapid metabolizer taking standard doses of codeine led the FDA to add a black box warning to codeine and to restrict its use in breastfeeding mothers and pediatric patients. This single example illustrates why metabolizer phenotype is clinically consequential, not an academic curiosity.

Clopidogrel is an antiplatelet prodrug that requires cytochrome P450 2C19 enzyme activity to generate its active metabolite, which irreversibly inhibits platelet aggregation. In poor metabolizers of cytochrome P450 2C19 — a group that includes a significant proportion of East Asian patients and a smaller but meaningful proportion of European patients — clopidogrel activation is severely impaired. These patients have inadequate platelet inhibition at standard doses and are at elevated risk of stent thrombosis and recurrent myocardial infarction after percutaneous coronary intervention. The FDA added a black box warning stating that poor metabolizers may not receive full benefit from clopidogrel and that testing is available to identify them.

Warfarin is metabolized primarily by cytochrome P450 2C9. Poor metabolizers of this enzyme have markedly reduced warfarin clearance and require substantially lower doses to achieve therapeutic anticoagulation — sometimes as little as half the typical dose. Cytochrome P450 2C9 genotyping is one component of pharmacogenomic-guided warfarin dosing algorithms, alongside variants in the vitamin K epoxide reductase gene that affects warfarin’s pharmacodynamic target.

Thiopurine methyltransferase is the enzyme that inactivates thiopurine drugs including azathioprine and 6-mercaptopurine, which are used in inflammatory bowel disease, organ transplant immunosuppression, and leukemia. Approximately one in three hundred patients is a thiopurine methyltransferase poor metabolizer, carrying two non-functional alleles. In these patients, standard thiopurine doses are not inactivated normally; instead, they are shunted into pathways that generate toxic active metabolites at high concentrations, causing profound bone marrow suppression that can be fatal. Testing thiopurine methyltransferase activity or genotype before starting thiopurine therapy is standard practice and can prevent this predictable, catastrophic adverse effect.

Some severe immune-mediated drug reactions are tightly associated with specific variants in human leukocyte antigen genes. These variants alter the way the immune system presents drug molecules to T lymphocytes, triggering a damaging immune response in susceptible individuals. The most clinically established example is the association between the HLA-B*5701 allele and abacavir hypersensitivity. Abacavir, an antiretroviral drug used in HIV treatment, causes a severe and potentially fatal hypersensitivity syndrome in approximately 8 percent of patients — but almost exclusively in those who carry HLA-B*5701. Prospective genotyping before initiating abacavir is now mandated in all HIV treatment guidelines and has virtually eliminated abacavir hypersensitivity in genotyped populations. HLA-B*1502 is similarly associated with severe cutaneous reactions to carbamazepine in Southeast Asian populations, leading to mandatory pre-treatment testing recommendations in those populations.

The kidney eliminates drugs and water-soluble metabolites into urine. When glomerular filtration rate falls — whether from chronic kidney disease, acute kidney injury, or age-related decline — renally cleared drugs accumulate with repeated dosing because each dose is eliminated more slowly than in a patient with normal kidney function. The effective half-life of these drugs is prolonged in proportion to the degree of renal impairment.

Clinical management requires identifying which drugs are renally cleared, estimating the patient’s current kidney function using the creatinine-based estimated glomerular filtration rate, and applying dose adjustments specified in prescribing references. The adjustment may take the form of a reduced dose at the same interval, a lengthened dosing interval, or both. For drugs with a narrow therapeutic index that are renally cleared — digoxin, aminoglycoside antibiotics, lithium, metformin, and many direct oral anticoagulants — failure to adjust can result in serious or fatal toxicity.

The liver is the primary site of drug metabolism and also synthesizes albumin, the principal plasma protein for drug binding. In patients with significant hepatic impairment from cirrhosis, hepatitis, or other liver disease, three pharmacokinetic problems can arise simultaneously. First, reduced enzyme activity impairs phase I and phase II metabolism, reducing drug clearance and increasing plasma concentrations at standard doses. Second, reduced albumin synthesis increases the free fraction of highly protein-bound drugs, amplifying their pharmacological and toxic effects. Third, portosystemic shunting in advanced cirrhosis allows orally absorbed drug to bypass the liver almost entirely, dramatically increasing the oral bioavailability of drugs that normally undergo significant first-pass extraction.

Hepatic dosing adjustment is more complex than renal adjustment because there is no single laboratory test that quantifies hepatic drug-metabolizing capacity the way creatinine quantifies glomerular filtration rate. Clinical scoring systems such as the Child-Pugh score provide an estimate of hepatic functional reserve that guides dose adjustment recommendations in prescribing references. Drugs that are entirely eliminated by the liver require particular caution in patients with severe hepatic impairment, and some drugs are contraindicated in this setting.